{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:08:09Z","timestamp":1792843689664,"version":"4.5.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Tacrolimus (TAC) dosing is typically guided by the trough concentration (C0). Yet, significant relationships between TAC C0 and clinical outcomes have seldom been reported or only with adverse events. Large retrospective studies found a moderate correlation between TAC C0 and the area under the curve (AUC), where, for any given C0 value, the AUC varied 3- to 4-fold between patients (and vice versa). However, no randomized controlled trial evaluating the dose adjustment based on TAC AUC has been conducted yet. A few observational studies have shown that the AUC is associated with efficacy and, to a lesser extent, adverse effects. Other studies showed the feasibility of reaching predefined target ranges and reducing underexposure and overexposure. TAC AUC<jats:sub>0\u201312 h<\/jats:sub> is now most often assessed using Bayesian estimation, but machine learning is a promising approach. Microsampling devices are well accepted by patients and represent a valuable alternative to venous blood sample collection during hospital visits, especially when a limited sampling strategy is required. As AUC monitoring cannot be proposed very frequently, C0 monitoring has to be used in the interim, which has led to fluctuating doses in patients with an AUC\/C0 ratio far from the population mean, because of different dose recommendations between the 2 biomarkers. We proposed estimating the individual AUC\/C0 ratio and derived individual C0 targets to be used in between or as a replacement for AUC monitoring. Existing technology and evidence are now sufficient to propose AUC monitoring interspersed with individualized-C0 monitoring for all patients with kidney transplants while collecting real-world data to strengthen the evidence.<\/jats:p>","DOI":"10.1097\/ftd.0000000000001266","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T21:00:28Z","timestamp":1727902828000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Getting Tacrolimus Dosing Right"],"prefix":"10.1097","volume":"47","author":[{"given":"Pierre","family":"Marquet","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, France; and"},{"name":"Pharmacology & Transplantation, UMR1248 Inserm, Universit\u00e9 de Limoges, CHU de Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/tri.12155","article-title":"Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics","volume":"26","author":"Israni","year":"2013","journal-title":"Transpl Int."},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/ajt.12191","article-title":"Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(\u2020)","volume":"13","author":"Bouamar","year":"2013","journal-title":"Am J Transpl."},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","article-title":"Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis","volume":"12","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2012","journal-title":"Am J Transpl."},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0b013e318030a40b","article-title":"Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans","volume":"29","author":"B\u00f6hler","year":"2007","journal-title":"Ther Drug Monit."},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1373\/clinchem.2014.223511","article-title":"Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes","volume":"60","author":"Noceti","year":"2014","journal-title":"Clin Chem."},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int."},{"key":"R8-20250108","first-page":"393","article-title":"Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation","volume":"32","author":"Rozen-Zvi","year":"2017","journal-title":"Nephrol Dial Transpl."},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.14504","article-title":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","volume":"18","author":"Davis","year":"2018","journal-title":"Am J Transplant"},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","article-title":"Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group","volume":"64","author":"Mayer","year":"1997","journal-title":"Transplantation"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","year":"1994","journal-title":"N Engl J Med."},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/FTD.0000000000001035","article-title":"Longitudinal exposure to tacrolimus and new-onset diabetes mellitus in renal transplant patients","volume":"45","author":"Destere","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin Pharmacol Ther."},{"key":"R14-20250108","first-page":"1107","article-title":"FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization","volume":"27","author":"Schwartz","year":"1995","journal-title":"Transpl Proc"},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00007691-199902000-00002","article-title":"Clinical pharmacokinetics of tacrolimus in heart transplant recipients","volume":"21","author":"Regazzi","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00007691-199804000-00014","article-title":"An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants","volume":"20","author":"Ku","year":"1998","journal-title":"Ther Drug Monit."},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.phrs.2017.12.005","article-title":"Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients","volume":"129","author":"Marquet","year":"2018","journal-title":"Pharmacol Res."},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FTD.0b013e318285e779","article-title":"Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure","volume":"35","author":"Saint-Marcoux","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/FTD.0000000000000503","article-title":"Pharmacokinetic therapeutic drug monitoring of advagraf in more than 500 adult renal transplant patients, using an expert system online","volume":"40","author":"Marquet","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/TP.0b013e3182962cc1","article-title":"Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients","volume":"96","author":"Gaber","year":"2013","journal-title":"Transplantation"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/lt.23844","article-title":"Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients","volume":"20","author":"Alloway","year":"2014","journal-title":"Liver Transpl."},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1586\/1744666X.2014.983903","article-title":"Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations","volume":"10","author":"Griny\u00f3","year":"2014","journal-title":"Expert Rev Clin Immunol."},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/FTD.0000000000000828","article-title":"Tacrolimus Bayesian dose adjustment in pediatric renal transplant recipients","volume":"43","author":"Marquet","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/cpt.2915","article-title":"Tacrolimus and mycophenolic acid exposure Are associated with biopsy-proven acute rejection: a study to provide evidence for longer-Term target ranges","volume":"114","author":"Meziyerh","year":"2023","journal-title":"Clin Pharmacol Ther."},{"key":"R25-20250108","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0041-1345(98)01633-9","article-title":"Low systemic exposure to tacrolimus correlates with acute rejection","volume":"31","author":"Undre","year":"1999","journal-title":"Transpl Proc"},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.clpt.2003.12.009","article-title":"Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients","volume":"75","author":"Kuypers","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/ctr.12581","article-title":"Switching study of kidney transplant patients with tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study","volume":"29","author":"Langone","year":"2015","journal-title":"Clin Transpl."},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003088-200443110-00005","article-title":"Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo renal transplant recipients","volume":"43","author":"Kuypers","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003088-200140050-00004","article-title":"Application of a gamma model of absorption to oral cyclosporin","volume":"40","author":"Debord","year":"2001","journal-title":"Clin Pharmacokinet."},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003088-200544120-00010","article-title":"Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies","volume":"44","author":"Saint-Marcoux","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FTD.0b013e3181cc70db","article-title":"Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation","volume":"32","author":"Saint-Marcoux","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40262-017-0533-5","article-title":"Population pharmacokinetics and Bayesian estimators for refined dose adjustment of a new tacrolimus formulation in kidney and liver transplant patients","volume":"56","author":"Woillard","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40262-020-00959-y","article-title":"Clinical pharmacokinetics and Bayesian estimators for the individual dose adjustment of a generic formulation of tacrolimus in adult kidney transplant recipients","volume":"60","author":"Marquet","year":"2021","journal-title":"Clin Pharmacokinet."},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11318080-000000000-00000","article-title":"Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients","volume":"48","author":"Benkali","year":"2009","journal-title":"Clin Pharmacokinet."},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/11535950-000000000-00000","article-title":"Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation","volume":"49","author":"Benkali","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2010.03837.x","article-title":"Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf","volume":"71","author":"Woillard","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11594760-000000000-00000","article-title":"Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation","volume":"51","author":"Monchaud","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00007691-200402000-00006","article-title":"Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator","volume":"26","author":"Rousseau","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40262-018-0687-9","article-title":"Comment on \u201cPopulation pharmacokinetics of mycophenolic acid: an update\u201d","volume":"57","author":"Woillard","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1111\/bcp.15857","article-title":"Tacrolimus population pharmacokinetics in adult heart transplant patients","volume":"89","author":"Paschier","year":"2023","journal-title":"Br J Clin Pharmacol."},{"key":"R41-20250108","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cpt.2123","article-title":"Tacrolimus exposure prediction using machine learning","volume":"110","author":"Woillard","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R42-20250108","doi-asserted-by":"crossref","first-page":"105578","DOI":"10.1016\/j.phrs.2021.105578","article-title":"Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus","volume":"167","author":"Woillard","year":"2021","journal-title":"Pharmacol Res."},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R44-20250108","doi-asserted-by":"crossref","first-page":"114443","DOI":"10.1016\/j.jpba.2021.114443","article-title":"Comparison of conventional dried blood spots and volumetric absorptive microsampling for tacrolimus and mycophenolic acid determination","volume":"208","author":"Paniagua-Gonz\u00e1lez","year":"2022","journal-title":"J Pharm Biomed Anal."},{"key":"R45-20250108","doi-asserted-by":"crossref","first-page":"340797","DOI":"10.1016\/j.aca.2023.340797","article-title":"Liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants and creatinine from a single dried blood spot using the Capitainer\u00ae qDBS device","volume":"1242","author":"Deprez","year":"2023","journal-title":"Anal Chim Acta"},{"key":"R46-20250108","doi-asserted-by":"crossref","first-page":"786","DOI":"10.5858\/arpa.2021-0533-OA","article-title":"Application of a fully automated dried blood spot method for therapeutic drug monitoring of immunosuppressants: another step toward implementation of dried blood spot analysis","volume":"147","author":"Deprez","year":"2023","journal-title":"Arch Pathol Lab Med."},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"123721","DOI":"10.1016\/j.jchromb.2023.123721","article-title":"New perspectives for the therapeutic drug monitoring of tacrolimus: quantification in volumetric DBS based on an automated extraction and LC-MS\/MS analysis","volume":"1223","author":"Ros\u00e9","year":"2023","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R48-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmsacl.2023.11.004","article-title":"Use of volumetric absorptive microsampling and parallel reaction monitoring mass spectrometry for tacrolimus blood trough measurements at home in pediatric heart transplant patients","volume":"31","author":"Zhao","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab."},{"key":"R49-20250108","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1111\/bcp.15433","article-title":"Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients","volume":"88","author":"Zwart","year":"2022","journal-title":"Br J Clin Pharmacol."},{"key":"R50-20250108","doi-asserted-by":"crossref","DOI":"10.1111\/petr.12983","article-title":"Longitudinal study on the use of dried blood spots for home monitoring in children after kidney transplantation","volume":"21","author":"Al-Uzri","year":"2017","journal-title":"Pediatr Transplant."},{"key":"R51-20250108","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jalm\/jfaa005","article-title":"Volumetric microsampling of capillary blood spot vs. whole blood sampling for therapeutic drug monitoring of tacrolimus and cyclosporin A: accuracy and patient satisfaction","volume":"5","author":"Mbughuni","year":"2020","journal-title":"J Appl Lab Med."},{"key":"R52-20250108","doi-asserted-by":"crossref","first-page":"11366","DOI":"10.3389\/ti.2023.11366","article-title":"Tacrolimus exposure before and after a Switch from twice-daily immediate-release to once-daily prolonged release tacrolimus: the ENVARSWITCH study","volume":"36","author":"Monchaud","year":"2023","journal-title":"Transpl Int."},{"key":"R53-20250108","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/bcp.14249","article-title":"Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: a randomized controlled hybrid implementation trial","volume":"86","author":"Veenhof","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"R54-20250108","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/TP.0000000000004405","article-title":"Can the area under the curve\/trough level ratio be used to optimize tacrolimus individual dose adjustment?","volume":"107","author":"Woillard","year":"2023","journal-title":"Transplantation"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:00:52Z","timestamp":1736348452000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001266","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"2024-06-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}